Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:  
The good — FDA approves Adaptimmune engineered cell therapy  
The bad — FDA puts clinical hold on vTv Therapeutics diabetes program  
The ugly — Sanofi sues Sarepta over manufacturing patents for Duchenne gene therapy

Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly]

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more